Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $140,000.

  • Keros Therapeutics' Cash from Financing Activities fell 99.91% to $140,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $75.7 million, marking a year-over-year decrease of 80.36%. This contributed to the annual value of $391.8 million for FY2024, which is 118.95% up from last year.
  • Keros Therapeutics' Cash from Financing Activities amounted to $140,000 in Q3 2025, which was up 723.53% from $17,000 recorded in Q2 2025.
  • Keros Therapeutics' 5-year Cash from Financing Activities high stood at $156.8 million for Q1 2024, and its period low was $4,000 during Q1 2025.
  • Over the past 3 years, Keros Therapeutics' median Cash from Financing Activities value was $3.5 million (recorded in 2024), while the average stood at $51.9 million.
  • As far as peak fluctuations go, Keros Therapeutics' Cash from Financing Activities surged by 138,708.57% in 2022, and later slumped by 100.00% in 2025.
  • Keros Therapeutics' Cash from Financing Activities (Quarterly) stood at $28.4 million in 2021, then surged by 116.13% to $61.4 million in 2022, then rose by 12.76% to $69.3 million in 2023, then increased by 9.08% to $75.5 million in 2024, then plummeted by 99.91% to $140,000 in 2025.
  • Its Cash from Financing Activities stands at $140,000 for Q3 2025, versus $17,000 for Q2 2025 and $4,000 for Q1 2025.